Provided by Tiger Trade Technology Pte. Ltd.

Sarepta Therapeutics

19.97
-1.7100-7.89%
Post-market: 20.020.0500+0.25%18:22 EDT
Volume:4.61M
Turnover:93.43M
Market Cap:2.09B
PE:-2.80
High:21.67
Open:21.67
Low:19.72
Close:21.68
52wk High:72.05
52wk Low:10.42
Shares:104.79M
Float Shares:95.17M
Volume Ratio:0.71
T/O Rate:4.84%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-7.1300
EPS(LYR):-7.1300
ROE:-53.47%
ROA:-11.24%
PB:1.83
PE(LYR):-2.80

Loading ...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Sarepta Therapeutics (SRPT) and InMode (INMD)

TIPRANKS
·
Jan 26

Sarepta rises 14.1%

TIPRANKS
·
Jan 26

Sarepta Therapeutics Shares Rise 6.7% Premarket After Co Reports Three-Year Data for Duchenne Muscular Dystrophy Gene Therapy

THOMSON REUTERS
·
Jan 26

Sarepta's Duchenne gene therapy slows disease progression at three years

Reuters
·
Jan 26

Sarepta reports ‘positive’ topline three-year EMBARK results for Elevidys

TIPRANKS
·
Jan 26

Sarepta Therapeutics Inc - No New Safety Signals Observed for Elevidys

THOMSON REUTERS
·
Jan 26

Sarepta Therapeutics Inc - Elevidys Shows 70% Reduction in Disease Decline Rate

THOMSON REUTERS
·
Jan 26

Sarepta Announces Positive Topline Three-Year Embark Results Showing Elevidys Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients

THOMSON REUTERS
·
Jan 26

Sarepta to report 3-year topline data from Embark Part 1 study

TIPRANKS
·
Jan 26

BUZZ-U.S. STOCKS ON THE MOVE-Baker Hughes, Allied Gold Corp, MannKind Corp

Reuters
·
Jan 26

Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT), Boston Scientific (BSX) and Brookdale Senior Living (BKD)

TIPRANKS
·
Jan 26

Sarepta Therapeutics Shares Climb 6% Premarket; Co to Release 3-Year Data for Muscle Dystrophy Gene Therapy

THOMSON REUTERS
·
Jan 26

BUZZ-Sarepta to release 3-year data for muscle dystrophy gene therapy; shares rise

Reuters
·
Jan 26

Stocks to Watch Monday: American Airlines, USA Rare Earth, RevMed -- WSJ

Dow Jones
·
Jan 26

A Look At Sarepta Therapeutics (SRPT) Valuation As EMBARK Phase 3 ELEVIDYS Readout Nears

Simply Wall St.
·
Jan 26

Sarepta Therapeutics Shares Rise on Planned Readout of Phase 3 Data

Dow Jones
·
Jan 24

BRIEF-Sarepta Therapeutics To Report 3-Year Topline Data From Embark Study Of Elevidys Gene Therapy

Reuters
·
Jan 24

Sarepta Therapeutics to Report 3-Year Topline Data From Embark Study of Elevidys Gene Therapy in Ambulatory Individuals With Duchenne Muscular Dystrophy

THOMSON REUTERS
·
Jan 24

Wedbush Raises Price Target on Sarepta Therapeutics to $34 From $32, Keeps Outperform Rating

MT Newswires Live
·
Jan 23

Sarepta Therapeutics Is Maintained at Outperform by Wedbush

Dow Jones
·
Jan 23